Precipitation of porphyria cutanea tarda by imatinib mesylate?

Ho, A Y L; Deacon, A C; Osborne, G; Mufti, Ghulam J.

doi:10.1046/j.1365-2141.2003.04277.x

Cited by 18 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Porphyria cutanea tarda (PCT) is an interesting adverse effect reported with imatinib treatment. Imatinib has been reported to cause both precipitation and reactivation of PCT . Curiously, imatinib has also been implicated in causing pseudoporphyria .…”

Section: Discussionmentioning

confidence: 99%

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…and Ho et al . reported two cases of porphyria cutanea tarda induced or reactivated by imatinib treatment (the serum porphyrin levels returned to normal and cutaneous lesions resolved on discontinuation of therapy) . A case of pseudoporphyria induced by imatinib has been described too .…”

Section: Imatinib Mesylatementioning

confidence: 99%

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience

Brazzelli

Grasso

Borroni

2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

In the last years, several tyrosine kinase inhibitors (TKIs) have been developed and approved for human cancer treatment. Imatinib mesylate was the first of this novel family of drugs that target cancer-specific molecules and signalling pathways. The appearance of imatinib resistances led to the introduction of second-generation TKIs with higher potency and selectivity, such as dasatinib and nilotinib. However, the range of activity of these agents is not simply directed at tumour cells. Patients and their clinicians are indeed frequently confronted with the cutaneous side-effects associated with the employ of these drugs, which represent the most common non-hematological adverse reactions. For this reason, a systematic dermatological survey of patients receiving these therapies is highly important, and an early and appropriate dermatological treatment is required. In this review, we analyse the clinical and pathological characteristics of the most commonly reported adverse skin events associated with first- and second-generation tyrosine kinase inhibitors, with a particular emphasis on our clinical experience.

show abstract

“…Their safety remains to be proven. For example, imatinib and bortezomib, which are targeted drugs, are suspected of having the potential to cause or reactivate porphyria cutanea tarda [54][55][56][57] . However, the literature on the use of old and new anticancer agents in patients suffering from porphyria is limited to a small number of patients, and any recommendations therefore cannot be based on a large body of evidence.…”

Section: Expert Opinionmentioning

confidence: 99%

Anticancer therapy in patients with porphyrias: evidence today

Thiery-Vuillemin

Chaigneau

Méaux-Ruault

et al. 2008

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Background : Porphyrias are rare diseases, and for these patients every administration of drugs may induce an acute attack of porphyria. The list of safe compounds allowed in these patients is available for clinicians from specific websites cited in the text. Objectives : However, data concerning anticancer therapy in patients with such diseases remain poor. Therefore any publications can help clinicians to deal with this very specific group of patients. Methods : In our institution, three patients received docetaxel and hematologic growth factors (erythropoietin and GCSF) without unexpected toxicities. Aromatase inhibitors (anstrozole and letrozole) were also given in one patient without any related problem. Conclusion : The present observation adds some useful data for the possible treatment of cancer in patients with porphyria.

show abstract

Precipitation of porphyria cutanea tarda by imatinib mesylate?

Cited by 18 publications

References 10 publications

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience

Anticancer therapy in patients with porphyrias: evidence today

Contact Info

Product

Resources

About